An interventional study of POCUS and Fixed Resuscitation Strategy based on Target MAP in Cirrhosis, Liver, Cirrhotic Cardiomyopathy and Septic Shock, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh — 3 open to participants now, 6 under way, none of them phase 3. Liver Cirrhosis · Post Graduate Institute of Medical Education and Research, Chandigarh.
Among the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 5 with no phase, and was the 16th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →3 of the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh are open now, in 1 country. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2016; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 141 across the 10 interventional studies, 142 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 43 are open to participants now.
1 of the studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06095466Post Graduate Institute of Medical Education and Research, ChandigarhCirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology | 2027-10-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Novelty:
Objectives:
Methods POC-ECHO will be done within 1 hours of admission to the liver ICU and at 24h, 48 h and 72 hours in patients with cirrhosis with systolic blood pressure of \<90 mmHg or a mean arterial pressure \<65 mmHg. Resuscitation target is maintenance of MAP ≥65 mmHg with use of fluids and/or vasopressors. Clinical, cardiac biomarkers, and survival data based on resuscitation fluids will be prospectively collected. CCM will be defined as per CCM Consortium (2020) criteria.
Expected outcome.
The key questions to be answered in the resuscitation of critically ill patients with cirrhosis and sepsis induced hypotension are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other Names: Point of Care- Echo-cardiogram,POCUS Description: • The patients in septic shock with MAP\< 65mmHg, with IVC diameter \<18mm and IVCCI≥40% in spontaneously breathing patients, would be regarded as fluid depleted state and will be given a fluid challenge with 250-500 ml of balanced salt solution. Those who increment cardiac index by 15% will be continued on fluid boluses with BSS and 5% albumin will be started as ongoing resuscitation within 1 h, which is a standard fluid of choice in patients with cirrhosis soon after the bolus BSS is infused. Fluids will be administered as per periodic POCUS with cardiac US targets, IVC, IJV indices, delta Velocity time integral, and maintenance of MAP\>65 mmHg. In the Intervention arm (ECHO) arm, we propose a dynamic Cardiac ultrasound target-based fluid resuscitation strategy.
Diagnostic Test: POCUS
Fixed Target Strategy Fluid boluses would be administered until a central venous pressure (CVP) of 8-10 mmHg is achieved. Till the central line is placed, the shock index (heart rate/ systolic blood pressure) will be used instead of the CVP and IVC indices. Thus fluids (500 ml balanced salt solution followed by 5% albumin) will be administered for a shock index ≥1 and till CVP is placed. • When CVP goal is achieved vasopressors will be started to target MAP ≥ 65mmHg. Once MAP target is achieved, ScVO2 ≥70% and lactate clearance \>10% will be targeted. • If ScVO2 is \<70% and lactate clearance is \<10%, noradrenaline will be started and titrated upwards. take it up to a maximum dose. • Second choice of pressor agent will be vasopressin. • Thus. CGDT group targets CVP, MAP, followed by ScVO2 ≥70% and lactate clearance .
Diagnostic Test: Fixed Resuscitation Strategy based on Target MAP
* In the Intervention arm (ECHO) arm, we propose a Cardiac ultrasound target-based fluid resuscitation. This incorporates the fluid assessment based on POCUS and myocardial dysfunction based on cardiac ultrasound (cardiac index, myocardial contractility, stroke volume) and portal hypertension-related systemic vasodilation accentuated by sepsis (systemic vascular resistance index or SVRI). * The POCUS -velocity time integral and stroke volume index will be used to determine fluid responsiveness. * If there is an increment in cardiac index by 15% after giving a fluid bolus (i.e. 250-500 ml of BSS in 15min), we can define 'fluid responsiveness' present. * The achievement of lactate clearance, MAP target \>65mmHg and ScV02 \>70% remains similar as the fixed target strategy. The main resuscitation fluid remains 5% albumin in this arm. Albumin infusion will be titrated based on lung ultrasound.
• Fluid boluses would be administered until a CVP of 8-10 mmHg is achieved and IVC diameter is between 1.8-2 cm with 20-30% collapsibility. Till the central line is placed, the shock index (heart rate/ systolic blood pressure) will be used instead of the CVP. Thus fluids (500 ml crystalloid followed by 5% albumin) will be administered for a shock index ≥1 and till CVP is placed. * When CVP goal is achieved vasopressors will be started to target MAP ≥ 65mmHg. Once MAP target is achieved, ScVO2 ≥70% and lactate clearance \>10% will be targeted. * If ScVO2 is \<70% and lactate clearance is \<10%, noradrenaline will be started and titrated upwards. take it up to a maximum dose. * Second choice of pressor agent will be vasopressin. * Thus. CGDT group targets CVP, MAP\>65 mmHg, followed by ScVO2 ≥70% and lactate clearance in a step wise way.
Reduction in volume of resuscitation fluid to attain reversal of shock in POCUS vs Conventional goal-directed therapy at 24 h
Dose of balanced salt solution (BSS) and 5% albumin in either arm
Time frame: Time of randomization to 24 hours
Assessment of all-cause mortality
Deaths due to liver related or non-liver related causes
Time frame: From time of randomization up to Day 7
Attainment of MAP> 65mmHg
Assessment of reversal of Shock with attainment of MAP target, and patient being off vasopressors
Time frame: from time of randomization up to time point of reversal of shock
Assessment of all-cause mortality
Time frame: From date of randomization until Day 28
Total dose of vasopressor usage in either arm.
Time frame: From date of randomization until 24 hours
Total dose of vasopressor usage in either arm.
Time frame: From date of randomization until Day 7
Duration of ICU stay.
Time frame: From date of randomization until discharge from ICU or death
Cardiac related biomarker panel test
NT proBNP, Plasma renin activity and galectin-3.
Time frame: At the Time of Randomization
Cardiac biomarker panel test
Level of NT proBNP, Plasma renin activity and galectin-3.
Time frame: The time point of 24 hours from randomization
Cardiac related biomarker panel test
NT proBNP, Plasma renin activity and galectin-3.
Time frame: At the Time point of 72h from randomization
Sepsis related biomarker panel test
sepsis biomarkers procalcitonin, endotoxin, IL-1, IL-6,
Time frame: At the Time of randomization
Sepsis related biomarker panel test
sepsis biomarkers procalcitonin, endotoxin, IL-1, IL-6,
Time frame: At the time point of 24 hours from randomization
Sepsis related biomarker panel test
sepsis biomarkers procalcitonin, endotoxin, IL-1, IL-6,
Time frame: At the Time point of 72 h from randomization
Development of any episode of AKI
Time frame: From randomization till 7 days from enrolment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Aug 2028, 31 months later.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 31 months is below that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post Graduate Institute of Medical Education and Research, Chandigarh →